

PRESS RELEASE

An award-winning breakthrough in personalised medicine

leon-nanodrugs GmbH (LEON) is proud to announce that its revolutionising nanoencapsulation equipment, the NANOME[®], just received an iF Design Award. The NANOME[®] is set to transform the manufacture of personalised medicines and improve patient access to these treatments.

NANOME[®] was developed by German pharmatech company LEON with support from medical technology consultants Team Consulting.

Personalised medicine is a relatively new treatment modality with great potential for combatting life-threatening cancers, cardiovascular diseases, and genetic disorders. For example, when treating conditions such as cancer, personalised treatments can be more effective compared to generalised treatments like chemotherapy, as they are manufactured specific to a patient's tumour. Despite their potential, access to these life-saving treatments is currently limited due to complex and expensive manufacturing processes.

Traditional biopharma facilities use process technologies and setups designed to manufacture high-volume batches of identical products. In personalised medicine, however, the target patient populations are very small—sometimes as small as one. Until now, the ability to process a high volume of small batches has been missing.

The NANOME[®] was developed to address exactly this challenge. It is an aseptic processing system for back-to-back personalised medicine with reliable quality batches. The innovative system transforms what is currently a lengthy process into a procedure that takes just minutes. "Recognising that the current reliance on open and operator-driven processes for advanced therapies manufacturing needs an overhaul, we have spearheaded the NANOME[®] system, which takes us one step closer to making personalised medicine into the mainstream," said Dr. Setu Kasera, Chief Scientific Officer at LEON.

The NANOME[®] has already been internationally recognised with an iF Design Award for its novel design and potential to impact patient lives. It is now set to transform the production of personalised medicine, enabling wider access to the patients that need it.

NOTES TO EDITORS

leon-nanodrugs GmbH is a Munich-based pharmatech company specializing in the development of devices for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). LEON builds its innovative solutions based on its proprietary FR-JET technology. Its portfolio of devices, NANOLab[®] for process development, and NANOME[®] and NANOUS[®] for GMP aseptic manufacturing, enable faster route to clinical batches and are suitable for both individualised scales and commercial production.

LEON's platform is aimed at enabling pharma companies, small biotech, research institutes, as well as CDMOs, to take full advantage of the significant progress being made in advanced therapies.

Team Consulting is an award-winning medical technology design and development consultancy. For the past 38 years they have helped innovative start-ups and global pharmaceutical companies develop state-of-the-art medical devices and technologies.



PRESS RELEASE

NANOme® is a benchtop device for GMP nanoparticle production. It is the only system that offers a fully-closed single-use sterile fluid path with zero contact between product and reusable parts for high sterility assurance. [Link to case study](#)

CONTACT LEON:

leon-nanodrugs GmbH

Maja Tinko-Kuhar, Marketing Manager

Phone: +49-89-41424889-98

e-mail: m.tinko-kuhar@leon-nanodrugs.com

CONTACT TEAM CONSULTING:

Team Consulting Ltd

Jack Jakins, Marketing Manager - Content

Mob: +44 7870548446

Email: jack.jakins@team-consulting.com